Navigation Links
Lack of Evidence on Treatment for Narrowed Kidney Arteries

han drug therapy alone.

* The evidence is inadequate to determine whether the treatments differ in lowering the risks of death, kidney failure, or heart disease.

* The risks of adverse events have not been adequately measured. Some studies suggested up to 3 percent of angioplasty patients died within 30 days. Other risks of angioplasty include kidney deterioration, injury to the renal artery or kidney tissue, and heart attack.

* Adverse events related to blood pressure medications (ACE inhibitors, beta blockers, and hydralazine) include dizziness when standing, problems with the digestive or nervous systems, and Raynaud’s syndrome, which restricts blood flow to the fingers and toes.

Source-Newswse
SRM
'"/>




Page: 1 2 3

Related medicine news :

1. Evidence Links Protein Damage to Neurodegenerative diseases like Parkinsons and Alzheimers
2. Evidence supporting H.pylori eradication
3. Evidence against use of Beta blockers as first choice in the treatment of primary hypertension
4. Evidences that Better Health Care Facility is Offered By Public Hospitals.
5. First Conclusive Evidence Linking Oral Bacteria To Premature Babies
6. Study Provides Evidence That Obesity Leads To A More Aggressive Ovarian Cancer
7. No Clear Evidence for Ultra-Low Cholesterol Targets?
8. Some Evidence Shows Chinese Herbal Medicine Helps Angina Patients
9. Strong Evidence Suggests Incidence Of Mating Of Ancestors With Neanderthals
10. Dermatologists Provide Unique Evidence of Possible Cause of Rare Skin Condition
11. Is Evidence-based Medicine Enough to Support Additional Research in Alternative Medicine?
Post Your Comments:
(Date:12/15/2009)... to Work For. , ... Alpharetta, GA (Vocus) Dec. ... provider of temporary physician and CRNA staffing, as the #4 Best ... , , ,“We are proud to be recognized on this list ... associates,” said R. Shane Jackson president of LocumTenens.com. “Unquestionably, we know ...
(Date:12/15/2009)... require that certain businesses with large areas where people gather, ... available. Fire and rescue personnel agree that for any size ... , ... Issaquah, WA (PRWEB) December ... that certain businesses with large areas where people gather, need ...
(Date:12/15/2009)... A study in the Dec. 15 issue ... indicates that significant associations exist between parent-reported ... and headaches in young school-aged children. , ... insomnia was 3.3 times more likely in children ... in children with headaches. Nineteen percent of ...
(Date:12/14/2009)... combination of AQUALIPO™ and NaturalFill™ revolutionary new liposuction and fat ... and plump lips all in one minimally invasive treatment. ... ... The combination of AQUALIPO™ and NaturalFill™ can remove excess fat ... lips to help people slim down, reduce facial wrinkling and ...
(Date:12/14/2009)... 14 Haemonetics Corporation (NYSE: ... a new legal action to stop Fenwal Inc.,s ... red cell collection kits, using a modified separation ... to circumvent Haemonetics, patent and the injunction entered ... infringing products after December 1, 2010. According ...
Breaking Medicine News(10 mins):Health News:LocumTenens.com Named 4th Best Staffing Firm to Work For 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 2Health News:QuickMedical Responds to Oregon Bill Requiring Businesses to Carry Defibrillators 3Health News:Insomnia symptoms linked with medical complaints in young school-aged children 2Health News:Insomnia symptoms linked with medical complaints in young school-aged children 3Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 2Health News: Free Webinar Series at Aqualipo.com Shows How New Combination Liposuction/Fat Transfer Treatment Helps Patients Slim Down and Reduce Facial Wrinkling 3Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 2Health News:Haemonetics Files a New Legal Action to Stop Fenwal Inc.'s Continued Patent Infringement 3
... Call on Friday, November 14th, FORT LAUDERDALE, Fla., ... leading provider of convenient at-home diet, fitness,and healthy lifestyle ... third quarter ended September 30, 2008, after the U.S.,equity ... company will also host a conference call for investors ...
... of Regence workers participate in annual giving effort, ... campaign record and bucked a national trend that threatens,charitable ... outlook -- or perhaps because of it --,Regence employees ... the company,s 50 percent match, local communities will,receive a ...
... for Medicare,& Medicaid Services (CMS) today announced that ... review 2009 Medicare,prescription drug plan and health plan ... and Medicare Options Compare at, http://www.medicare.gov ., ... throughout the upcoming,open enrollment period, for beneficiaries to ...
... Nov. 10 For Emmy-award winning actor Hector,Elizondo, the ... are very personal. In the 1960s, Elizondo,s mother was ... brain,causing impaired thinking, memory, and attention., For Elizondo,s ... a 24/7 commitment. Although the family was willing to ...
... Mich., Nov. 10 A study published today ... that annual,medical expenditures for Crohn,s disease patients are ... matched comparison group of patients. Similar,results were found ... examined both direct medical costs - inpatient and ...
... 10 Players for the NFL,s,Chicago Bears will visit ... North Chicago VA medical center, as part of the ... Jason McKie and running back Adrian Peterson are,scheduled to ... for serving,our nation by signing autographs, presenting patients with ...
Other Medicine News:Health News:eDiets.com(R) to Report Third Quarter 2008 Results on Thursday, November 13, 2008 2Health News:Trend-Breaking Employee Campaign Raises Nearly $2.5 Million 2Health News:Medicare's Online Tools Will Help Beneficiaries With Prescription Drug and Health Plan Choices for 2009 2Health News:Medicare's Online Tools Will Help Beneficiaries With Prescription Drug and Health Plan Choices for 2009 3Health News:Hector Elizondo: Caring for a Loved One with Alzheimer's Dementia 2Health News:Hector Elizondo: Caring for a Loved One with Alzheimer's Dementia 3Health News:Companies Pay a High Price for Employees With Crohn's Disease and Ulcerative Colitis, According to Study From Thomson Reuters 2
(Date:12/14/2009)... Embarrassing and sometimes uncomfortable colonoscopies may soon ... are taking note of a new screening test that ... The Knoxville-based company, EDP Biotech Corporation (EDP) ... affordable medical device doctors can use to screen for ... you consider that 30% of colon cancer deaths are ...
(Date:12/14/2009)... Dec. 14 Seven leading ... US Oncology Research participated ... at the 2009 San Antonio ... 9-13 at the Henry B. ... Antonio, Texas . Fifteen others ...
(Date:12/14/2009)... 14 Alexza Pharmaceuticals, Inc. (Nasdaq: ALXA ... Drug Application (NDA) for Staccato® loxapine (AZ-004) to the ... an inhalation product candidate being developed for the rapid ... disorder. The IND for Staccato loxapine ... "AZ-004 has delivered a predictable and consistent safety and ...
Breaking Medicine Technology:EDP Biotech Takes Next Step in the Development of ColoMarker 2EDP Biotech Takes Next Step in the Development of ColoMarker 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 2US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 3US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 4US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 5US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 6US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 7US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 8US Oncology Research Network Participates in Seven Oral Clinical Studies Presentations and 15 Posters at 2009 San Antonio Breast Cancer Symposium 9Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 2Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 3Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 4Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 5Alexza Announces Submission of AZ-004 (Staccato(R) Loxapine) NDA 6NEI Awards a Two Year 242 18 Million SBIR Grant to Aciont 15142 1NEI Awards a Two Year 242 18 Million SBIR Grant to Aciont 15142 2NEI Awards a Two Year 242 18 Million SBIR Grant to Aciont 15142 3Edifecs Testifies Before NCVHS Standards Subcommittee Regarding HIPAA 5010 and ICD 10 Testing 63056 1Edifecs Testifies Before NCVHS Standards Subcommittee Regarding HIPAA 5010 and ICD 10 Testing 63056 2Esperanza Health Center Receives 246 5 Million in Stimulus Funds 63051 1Esperanza Health Center Receives 246 5 Million in Stimulus Funds 63051 2
... 24 Anthera Pharmaceuticals,announced today they have ... Drug,Administration (FDA) on a Phase 3 protocol ... under the FDA,s Special Protocol Assessment,procedure. At ... Advice from,the European Medicines Agency (EMEA) on ...
... has Completed Recruitment of Patients in the Phase III ... in Rituximab Refractory Follicular NHL, COPENHAGEN, September 23 ... recruitment of patients in the,pivotal Phase III study of ... patients,receiving treatment at the 1000 mg dose level of ...
Other Medicine Technology:Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval 2Anthera Completes Special Protocol Assessment With FDA and Receives EMEA Scientific Advice on Development Path Toward Varespladib Approval 3Recruitment Completed in Ofatumumab NHL Pivotal Study 2Recruitment Completed in Ofatumumab NHL Pivotal Study 3
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... a national reference laboratory and a worldwide ... ARUP offers an extensive test menu of ... clinical and anatomic pathology. Owned by the ... more than half of the nation's university ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
... ARUP Laboratories is a national reference ... laboratory research and development. ARUP offers an ... unique medical tests in clinical and anatomic ... ARUP Laboratories' clients include more than half ...
Medicine Products: